Drug Combination Details
| General Information of the Combination (ID: C90372) | |||||
|---|---|---|---|---|---|
| Name | Theaflavin-3,3'-digallate + Black tea polyphenol | + | Cisplatin | ||
| Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
| Name | Theaflavin-3,3'-digallate NP Info | Drug Info | |||
| Structure |
|
|
|||
| Name | Black tea polyphenol NP Info | ||||
| Structure |
|
|
|||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G1/S phase | ||||
| Up-regulation | Cytochrome c release | |||||
| In-vitro Model | A2780/CP70 | CVCL_0135 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
| OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic effect of black tea polyphenol, theaflavin-3,3'-digallate with cisplatin against cisplatin resistant human ovarian cancer cells. J Funct Foods. 2018 Jul;46:1-11. | |||
